Intra-Cellular Therapies, a clinical-stage biotech developing treatments for neurological disorders, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The New York, NY-based company, which was founded in 2012, plans to list on the NASDAQ under the symbol ITCI. It is currently traded on the OTC market under the same ticker. Leerink Partners and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
